Search the Newsreel

Artelo Enrolls First Patient In Phase 2 DREAM Trial For ART27.13 In Treating Intralocular Pressure

(RTTNews) - Artelo Biosciences Inc. (ARTL), a clinical-stage pharmaceutical company, on Monday announced the enrollment of the first patient in the Phase 2 DREAM trial for ART27.13 in treating glaucoma or ocular hypertension. Glaucoma affects about 80 million people worldwide and often leads to …

Artelo Tests an Oral Cannabinoid for Glaucoma Eye Pressure

Artelo Biosciences has dosed the first patient in its Phase 2 DREAM study, evaluating the oral synthetic cannabinoid ART27.13 for glaucoma and ocular hypertension. The study, funded by Glaucoma UK and HSC R&D Division and led by Professor Augusto Azuara-Blanco, aims to assess ART27.13's …

Descartes Systems Group Stock Surges 1.95% as Logistics Software, AI and Global Trade Digitization Support Growth

Descartes Systems Group Inc. (TSX:DSG) saw its stock rise by 1.95% due to renewed investor interest in its logistics and supply-chain software. The company benefits from the increasing complexity of global trade, e-commerce growth, and the integration of AI in logistics, offering mission-critical solutions …

Standard Chartered PLC's Dividend Analysis

This article first appeared on GuruFocus. Assessing the Upcoming Payment and Long-Term Sustainability of Standard Chartered PLC (SCBFY) Standard Chartered PLC (SCBFY) recently announced a total dividend of $0.41 per share, with the ex-dividend date set for 2026-08-10. This upcoming payment includes a $0.41 …

Standard Chartered Sees $4T Tokenization Driving Chainlink to $200 by 2030

Standard Chartered has initiated coverage of Chainlink with a price target of $200 by the end of 2030, implying a roughly 25-fold gain from around $8 today and outperformance of both Bitcoin and Ethereum over the period. Geoff Kendrick, the bank's global head of …

Cartesian Therapeutics Advances RNA Cell Therapy Pipeline; Wedbush Sets $38 Price Target

Cartesian Therapeutics (RNAC) is advancing its RNA cell therapy pipeline, with its lead candidate, Descartes-08, an autologous RNA CAR-T therapy, holding significant potential for autoimmune diseases. Wedbush has set a price target of $38 for the company. The therapy has received FDA RMAT, Fast …

The Descartes Systems Group Inc.

U.S. container imports in July reached the fourth-highest level on record, according to supply chain technology provider Descartes Systems Group. Shippers increased imports in anticipation of potential U.S. tariff changes. This data highlights significant activity in global trade and logistics.

Arteris, Inc. (NASDAQ:AIP) Given Consensus Rating of "Moderate Buy" by Brokerages

Arteris, Inc. (NASDAQ:AIP) has received a "Moderate Buy" consensus rating from brokerages, with an average 12-month price target of $41.00. While the company exceeded revenue expectations in the second quarter and provided strong third-quarter and full-year guidance, it also reported a larger-than-expected loss per …

Descartes Systems Group Inc (DSGX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Artex Industrial Investment Logs Lower H1 Attributable Net Profit, Revenue

Did Arteris' (AIP) Raised 2026 Outlook and AI Wins Just Recast Its Investment Narrative?

Arteris, Inc. (AIP) recently reported its second-quarter 2026 results, showing increased revenue and a wider net loss, but also raised its full-year 2026 revenue outlook. The company highlighted record contract values, significant AI and data center design wins, and new capital raised, which strengthens …

Where Does Charter Hall Retail REIT (ASX:CQR) Valuation Sit Following Its FY26 Results?

Cartesian Therapeutics (NASDAQ:RNAC) Announces Quarterly Earnings Results

Cartesian Therapeutics (NASDAQ:RNAC) announced its quarterly earnings, reporting an EPS of $0.46, significantly beating the consensus estimate of a $0.88 loss. Following the announcement, RNAC shares rose 1.0% to $8.85, with analysts maintaining a "Moderate Buy" rating and an average price target of $32.60. …

Arrowstreet Capital Limited Partnership Decreases Stock Holdings in Carter Bankshares, Inc. $CARE

Arrowstreet Capital Limited Partnership significantly reduced its stake in Carter Bankshares, Inc. (NASDAQ:CARE) by 75.2% in the first quarter, now holding 11,601 shares valued at $271,000. Other institutional investors have also adjusted their positions in the company. Carter Bankshares reported disappointing Q1 earnings, missing …

Arteris Inc (AIP) Earnings Forecast: Future EPS & Revenue Growth Estimates

Price to sales forward of Artelo Biosciences, Inc. – NASDAQ:ARTL

This article displays the "Price to sales forward" metric for Artelo Biosciences, Inc. (NASDAQ: ARTL) on the TradingView platform. It provides financial data for the company, noting the market is currently closed with no trades. The primary content is a financial data point for …

Enterprise value to revenue forward of Artelo Biosciences, Inc. – NASDAQ:ARTL

Here's Why We Think RACL Geartech (NSE:RACLGEAR) Might Deserve Your Attention Today

A Quick Look at Today's Ratings for Cartesian Therapeutics(RNAC.US), With a Forecast Between $25 to $44

This article provides an overview of recent analyst ratings for Cartesian Therapeutics (RNAC.US), highlighting a price target forecast ranging from $25 to $44. It indicates that the company has received a "Strong Buy" consensus from analysts, based on positive evaluations over the past three …

Cartesian Therapeutics (NASDAQ:RNAC) Upgraded by Wall Street Zen to Hold Rating

Cartesian Therapeutics (NASDAQ:RNAC) was upgraded by Wall Street Zen from a "sell" to a "hold" rating. Despite this upgrade, the company still holds a "Moderate Buy" consensus rating among analysts with an average price target of $32.60. Institutional investors own a significant portion of …

Carter's (CRI) Posts Stronger Earnings And New Guidance, Is It Still Below Fair Value?

Arteris, Inc. Stock 12‑Month Price Target Raised to $41, Implies 30% Upside

The average 12-month price target for Arteris, Inc. (AIP) stock has been raised from $39.33 to $41 by 6 analysts, with forecasts ranging from $38 to $50 per share. This new target suggests a potential upside of approximately 30% from the Aug. 6 closing …

Sei Investments Co. Increases Stake in Marten Transport, Ltd. $MRTN

Sei Investments Co. significantly increased its stake in Marten Transport, Ltd. by 79.1% in the first quarter, now holding 220,314 shares valued at $2.9 million. Despite institutional ownership collectively reaching 69.12% and analysts maintaining a "Moderate Buy" consensus, Marten Transport recently missed quarterly earnings …

Arteris (AIP) Stock Revenue Growth Collides With Widening Losses

Arteris (AIP) reported strong Q2 2026 revenue of US$24.1 million, driven by record annual contract value and royalties, indicating solid demand for its chip networking IP, particularly from AI and data center sectors. However, investor sentiment was negative due to widening losses, with net …

Carter Bankshares (NASDAQ:CARE) Lowered to "Hold" Rating by Wall Street Zen

Wall Street Zen has downgraded Carter Bankshares (NASDAQ:CARE) to a "Hold" rating from "Buy," aligning with the majority of analysts who also rate the stock as "Hold." This downgrade follows the company's recent earnings report, which significantly missed consensus estimates for both EPS and …

Charter Hall Stock And 2 More Shares Linked To Retiree Spending

Carter's (CRI) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Friday, July 31, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer and President - Sharon Price JohnChief Financial Officer and Chief Operating Officer - Richard WestenbergerChief Retail and Digital Officer - Allison PetersonVice President, Investor Relations …

Charter Prices $4.75 Billion Senior Secured Notes

Charter Communications, Inc. announced that its subsidiaries, Charter Communications Operating, LLC and Charter Communications Operating Capital Corp., have priced $4.75 billion in aggregate principal amount of senior secured notes with varying interest rates and due dates. The net proceeds are intended to fund the …

Charter Hall Retail REIT Earnings: Property Values Rise; Securities Undervalued

Artesian Resources (Nasdaq: ARTNA) grows Q2 2026 revenue 7.4%

Artesian Resources Corporation reported increased earnings and revenue for the second quarter and first half of 2026. Q2 diluted EPS rose 4.9% to $0.64, with revenue climbing 7.4% to $30.7 million, driven by temporary rate increases, customer growth, and higher wastewater activity. The company …

Descartes Systems Group Inc (DSGX) Stock News Today

Jefferies upgrades Arteris stock rating on profitability outlook

Jefferies has upgraded Arteris Inc. (NASDAQ:AIP) stock rating from Hold to Buy and increased its price target to $50.00, citing increased comfort with the company's path to non-GAAP profitability. The firm expects Arteris to achieve profitability by Q4 2026, driven by an 88% gross …

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics, Inc. announced the granting of inducement awards to four new employees, consisting of options to purchase 115,250 shares of the Company’s common stock. These options have an exercise price equal to the closing trading price on their respective grant dates of August …

Four new employees get options for 115,250 Cartesian shares

Cartesian Therapeutics (NASDAQ: RNAC) has granted stock options for an aggregate of 115,250 common shares to four new employees, with grant dates of August 3 and August 6, 2026. These options have an exercise price equal to the closing Nasdaq Global Market price on …

Cartesian Therapeutics 2Q Research and Development Expenses $20.4M >RNAC

Cartesian Therapeutics reported research and development expenses of $20.4 million for the second quarter. This financial detail is a key indicator of the company's investment in its pipeline and future growth. The article focuses solely on this financial reporting without further elaboration.

Cogent Communications Holdings Inc (CCOI) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen